Adding Talazoparib to Enzalutamide Appears Beneficial in mCRPC With HRR Mutations
Adding talazoparib to first-line treatment with enzalutamide improves rPFS in patients with HRR-deficient mCRPC, a phase 3 trial suggests.
Prostate Cancer News
PROSTATE CANCER ADVISOR
Prostate Cancer News
Lynparza Combo Approved for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
The approval was based on data from the phase 3 PROpel trial.
Imaging Agent Posluma Approved to Aid in Prostate Cancer Detection
The approval was based on data from the LIGHTHOUSE and SPOTLIGHT trials.
Second-Generation Antiandrogens Linked to Falls, Cognitive Toxicity in Prostate Cancer Patients
Prostate cancer patients treated with second-generation antiandrogens may have an increased risk of falls, fatigue, and cognitive toxicity.
Real-World mCSPC First-Line Treatment Intensification Remains Low
Study findings highlight the need for earlier mCSPC treatment intensification by urologists and oncologists.
The EMBARK Trial: An Interview With Neal D. Shore, MD
The phase 3 EMBARK trial involved more than 200 global sites and had 8 years of follow-up.
Cancer Death Rates Vary Across Congressional Districts
Cancer death rates in the US have declined in recent years, but the declines vary by congressional district, a study suggests.
Adding ADT to RT Improves Some Outcomes in Intermediate-Risk Prostate Cancer
Adding 6 months of ADT to dose-escalated RT does not improve overall survival but does reduce prostate cancer-specific death, a study suggests.
Prostate Cancer in Transgender Women May Be More Common Than Previously Thought
New research indicates that prostate cancer among transgender women is not as rare as previous case reports suggest.
Prostate Cancer Hits Patients With Substantial Out-of-Pocket Expenses
Patients with localized prostate cancer may face substantial out-of-pocket expenses up to 24 months after diagnosis, a survey suggests.
Prostate Cancer Diagnoses, Treatment Patterns Changed Due to COVID-19 Pandemic
Patients diagnosed with prostate cancer during the first year of the COVID-19 pandemic were more likely to have higher-risk disease and less likely to receive definitive treatment.
Adding ADT to MDT Improves Outcomes in Oligometastatic CSPC
Men with oligometastatic castration-sensitive prostate cancer have improved outcomes when ADT is added to MDT.
Locally Advanced, Low Metastatic Burden Prostate Cancer Have Similar Outcomes
Patients with locally advanced and low metastatic burden prostate cancer have similar oncologic outcomes when treated with ADT alone.
Radical Treatments May Not Decrease Prostate Cancer-Specific Mortality
Patients with localized prostate cancer have similar cancer-specific mortality whether they undergo surveillance, surgery, or radiotherapy, a study suggests.
Black Men With Metastatic Prostate Cancer More Frequently Refuse Chemotherapy
A recent study revealed a racial disparity in the use of guideline-concordant treatment for metastatic prostate cancer.
Newly Identified Prostate Cancer Subtypes May Respond Differently to Treatment
Researchers say they have identified 4 subtypes of prostate cancer with distinct biological and clinical features, and these subtypes may respond differently to treatment.
Camonsertib-PARP Inhibitor Combos May Meet Unmet Need in Advanced Solid Tumors
Combining camonsertib with PARP inhibitors may be an effective strategy for treating advanced solid tumors, a study suggests.
Men 70 and Older Still Overscreened for Prostate Cancer
Men aged 70 years or older continue to be screened for prostate cancer despite USPSTF recommendations against it.
Metastasis-Directed Therapy Improves PFS in Oligometastatic Prostate Cancer
Adding MDT to intermittent hormone therapy improves disease control in oligometastatic prostate cancer, a phase 2 trial suggests.
Risk of Drug-Drug Interactions in Patients With HIV and Cancer
As many as 1 in 4 patients receiving treatment for cancer and HIV may be at risk of experiencing drug-drug interactions, according to researchers.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...